Background: The advent of COVID-19 vaccinations saw a rise in myopericarditis cases among young adults all over the United States, especially among males. As of June 11, 2021, 21.5 million second doses of COVID-19 vaccines have been administered in the age group 12 to 29, with 455 reported cases of myocarditis. Purpose: This report outlines a case of myopericarditis diagnosed in the first female young adult in the state of Mississippi after administering the second dose of the Pfizer- BioNTech BNT162b2 mRNA COVID-19 vaccine. The purpose of this case report is to discuss the presentation of myocarditis in a female patient, and the implications of vaccine use in the future. Conclusion: Myocarditis was found to be a rare occurrence among those vaccinated (risk of 0.0021%) compared to those who contract the COVID-19 infection (risk of 0.098%). ACIP recommends COVID-19 vaccinations to be administered in all age groups given the high risk-benefit ratio. In the meantime, CDC continues to investigate myocarditis cases post COVID-19 vaccinations and have found majority of these individuals to have recovered completely. However, the long-term effects of myopericarditis post vaccinations have yet to be determined.


To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.